Ascent Industries Co. (ACNT) reported a net loss of $1.0 million for the fourth quarter of 2025, with net sales of $18.8 million and a gross profit of $3.4 million, giving a gross margin of 18.3% versus 19.2% in Q4 2024. The company’s earnings per share for the quarter were –$0.11, a miss of $0.27 against the consensus estimate of $0.16, reflecting the impact of higher material and fulfillment costs and a less favorable product mix.
For the full year, ACNT’s net sales fell 7.3% to $74.9 million, while gross profit rose to $17.2 million, expanding the gross margin to 23.0% from 13.2% in 2024. Adjusted EBITDA for the year was a loss of $0.6 million, a significant improvement over the $4.7 million loss in 2024. When discontinued operations are included, the company posted a net income of $867,000, but the net loss from continuing operations remained $5.6 million. Earnings per share for the year were –$0.11, missing the consensus estimate of $0.16 by $0.27.
The company repurchased 19,749 shares during the quarter at an average price of $13.23, spending roughly $0.3 million, and bought back 745,524 shares for the year at $12.26 each, totaling about $9.2 million. ACNT ended 2025 with $57.6 million in cash and cash equivalents and no debt, underscoring a strong liquidity position that supports ongoing share‑buyback activity and future investment.
CEO Bryan Kitchen emphasized that the quarter’s results reflected “normal seasonal softness, compounded by continued market softness across several end markets.” He noted that the company’s “progress delivered across the full year underscores the strengthening earnings profile of the business,” and highlighted the divestiture of the Tubular Products segment (BRISMET and ASTI) and an asset carve‑out that helped streamline operations. Kitchen said the company is “entering 2026 with a clean, focused, specialty chemicals platform” and that it is “targeting margins in the 30% to 35% range that flow through to SG&A at 15%.” He added that a sizable new program announced in December is expected to reach full run rate in early Q2 2026, supporting a plan for double‑digit revenue growth in 2026.
Investors reacted negatively to the earnings release, largely because the company missed both EPS and revenue estimates. The significant miss on EPS and the 61.6% shortfall in revenue relative to consensus underscored concerns about near‑term demand softness and the impact of higher costs on profitability.
The company’s valuation appears attractive, with a forward price‑to‑sales ratio of 0.70 versus a five‑year average of 2.79. Coupled with its strong liquidity, absence of debt, and the strategic shift to a high‑margin specialty chemicals platform, ACNT’s outlook includes the potential for double‑digit revenue growth in 2026 and continued margin expansion as new programs mature.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.